2024 Rome, Italy

II-01 Åsa Kragh
Population pharmacokinetic analysis of PT010, an inhaled triple fixed-dose combination product, in patients with chronic obstructive pulmonary disease
Wednesday 15:10-16:40
II-02 Markus Krauß
Mice with human livers improve First-in-Human prediction of pharmacokinetics
Wednesday 15:10-16:40
II-03 Rukmini Kumar
Quantitative Systems Pharmacology (QSP) tools to aid in model development and communication: Vantage QSP Modeling Tools (VQM-Tools)
Wednesday 15:10-16:40
II-04 Hanna Kunina
Diabetes progression modelling of competing risks of long-term complications and mortality using Swedish registry data
Wednesday 15:10-16:40
II-05 Sofiene Laarif
Quantitative modeling of inter-lesion and inter-organ variability of tumor size
Wednesday 15:10-16:40
II-06 Jennifer Lang
Combining physiologically-based-pharmacokinetic modelling and a Bayesian method for prediction of ivabradine oral absorption and drug-drug interactions
Wednesday 15:10-16:40
II-07 Silvia Maria Lavezzi
Pharmacokinetic Models for Drug and Metabolites Including First Pass Effects: A Priori and A Posteriori Identifiability Analysis
Wednesday 15:10-16:40
II-08 Jean Lavigne
Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population
Wednesday 15:10-16:40
II-09 Jacob Leander
Development of a population pharmacokinetic model of verinurad used for simulations of various dosing scenarios in different populations
Wednesday 15:10-16:40
II-10 Donghwan Lee
Effect of Pharmacokinetic Model Misspecification on Antibiotic Probability of Target Attainment Predicted by Monte Carlo Simulation
Wednesday 15:10-16:40
II-11 Woo Yul Lee
Population pharmacokinetics of recombinant coagulation factor VIII in Korean hemophila A patients
Wednesday 15:10-16:40
II-12 Soyoung Lee
Population Pharmacokinetic Analysis for Novel Acid Pump Antagonist DWP14012
Wednesday 15:10-16:40
II-13 Hyun A Lee
A mechanism-based pharmacokinetic/pharmacodynamic model to evaluate the mutual relationships between YH4808, a novel K+-competitive acid blocker, and intragastric pH in humans
Wednesday 15:10-16:40
II-14 So Jin Lee
The new era of pharmacokinetic/pharmacodynamic modeling and simulation in drug development in Korea
Wednesday 15:10-16:40
II-15 Anja Lehmann
Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach
Wednesday 15:10-16:40
II-16 Rory Leisegang
Establishing evidence for improved outcomes for HIV+ patients receiving antiretroviral drugs through home delivery
Wednesday 15:10-16:40
II-17 Giulia Lestini
Handling dropouts in longitudinal observational studies – an illustration of a workflow from data preparation to model building and model diagnostics in Alzheimer’s disease
Wednesday 15:10-16:40
II-18 Yisheng Li
A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling
Wednesday 15:10-16:40
II-19 Patrick Lilienthal
Mathematical modeling of RBC count dynamics after blood loss
Wednesday 15:10-16:40
II-20 Dan Liu
Investigating Impacts of Model Parameters Correlations in Global Sensitivity Analysis: Determining the most influential parameters of a Minimal PBPK Model of Midazolam
Wednesday 15:10-16:40
II-21 Feiyan Liu
Modeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide
Wednesday 15:10-16:40
II-22 Carolina Llanos-Paez
Implementation of event time distribution as a random effect in time-to-event analysis
Wednesday 15:10-16:40
II-23 Rasmus Jansson Löfmark
Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure target engagement
Wednesday 15:10-16:40
II-24 Aurelie Lombard
Tumour size measurements: impact of inter-operator variability on model-based drug effect evaluation
Wednesday 15:10-16:40
II-25 Dominik Lott
Prediction of exposure and effect on total lymphocyte count following long-term treatment of healthy subjects and lupus patients with the selective S1P1 receptor modulator cenerimod
Wednesday 15:10-16:40
II-26 Qiang Lu
Population Pharmacokinetic Meta-Analysis of Dupilumab in Adult Atopic Dermatitis Patients, Asthma Patients, and Healthy Subjects
Wednesday 15:10-16:40
II-27 Inga Ludwig
A Quantitative Approach to Assess Similarity of Adult and Pediatric Efficacy to Support Full or Partial Extrapolation in Pediatric Drug Development
Wednesday 15:10-16:40
II-28 Ulrich Ruben Luecht
Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine
Wednesday 15:10-16:40
II-29 Nicolas Luyckx
Improving the performances of clinical trial simulations in Simulo using compiled code
Wednesday 15:10-16:40
II-30 Yassine Kamal Lyauk
Dose Finding in Clinical Development of 60 FDA-Approved Drugs Compared to the Learning versus Confirming Paradigm
Wednesday 15:10-16:40
II-31 Sreenath M Krishnan
A combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients
Wednesday 15:10-16:40
II-32 Guangda Ma
Evaluating the influence of genotype on warfarin dose predictions made using a theory-based PKPD model.
Wednesday 15:10-16:40
II-33 Panos Macheras
On the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants
Wednesday 15:10-16:40
II-34 Paolo Magni
Artificial intelligence and machine learning: just a hype or a new opportunity for pharmacometrics?
Wednesday 15:10-16:40
II-35 Mats Magnusson
Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis
Wednesday 15:10-16:40
II-36 Corinna Maier
Quantifying the uncertainty: informative decision-support in individualised chemotherapy
Wednesday 15:10-16:40
II-37 Victor Mangas-Sanjuan
Population Pharmacokinetic and exposure-efficacy Markov modelling of enzymatic activity in Gaucher disease patients treated with enzyme replacement therapy
Wednesday 15:10-16:40
II-38 Nicolás Marco Ariño
Pharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery
Wednesday 15:10-16:40
II-39 Fatima Zahra Marok
Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine
Wednesday 15:10-16:40
II-40 Frederico Martins
Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection.
Wednesday 15:10-16:40
II-41 Paolo Mazzei
Prospective Evaluation of a Model-Based approach to select Phase 1 Dosing Regimen for MEN1309/OBT076, a novel antibody drug conjugate (ADC) targeting Ly75 antigen for the treatment of CD205-positive metastatic solid tumours and Non-Hodgkin lymphoma
Wednesday 15:10-16:40
II-42 Mark Meerson
Quantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease
Wednesday 15:10-16:40
II-43 Christophe Meille
Combining BLRM and safety PKPD models to improve decision making in a phase I dose escalation study: case study of PCA062, an antibody drug conjugate targeting P-Cadherin
Wednesday 15:10-16:40
II-44 Nicola Melillo
Global sensitivity analysis of a physiologically based pulmonary absorption model
Wednesday 15:10-16:40
II-45 France Mentré
New version of PFIM for optimal design in nonlinear mixed effects models using R S4
Wednesday 15:10-16:40
II-46 Matilde Merino-Sanjuán
Impact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5'-deoxy-5-fluorouridine (5'-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer
Wednesday 15:10-16:40
II-47 Danica Michalickova
Pharmacokinetics of phenobarbital in neonates on extracorporeal membrane oxygenation
Wednesday 15:10-16:40
II-48 Robin Michelet
A workflow for application of the general pharmacodynamic interaction model on high-throughput combinatorial data in order to identify, quantify and characterise drug combinations that can overcome multi-drug-resistance
Wednesday 15:10-16:40
II-49 Iris Minichmayr
Impact of genetic variants of UGT1A1 on myelosuppression during irinotecan therapy
Wednesday 15:10-16:40
II-50 Jonathan Mochel
A Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species
Wednesday 15:10-16:40
II-51 Daniel Moj
Biotest’s Pentaglobin® in adults and neonates (term and preterm) – A PBPK approach
Wednesday 15:10-16:40
II-52 Camille Riff
Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia
Wednesday 15:10-16:40
II-53 Anna Mc Laughlin
Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics
Wednesday 15:10-16:40
II-54 Flora Musuamba Tshinanu
Dose optimization based on control and system theory: Case of Meropenem
Wednesday 15:10-16:40
II-55 Tadakatsu Nakamura
A Model-Based Meta-Analysis (MBMA) of Efficacy of Different Drugs for Postmenopausal Vasomotor-Symptoms
Wednesday 15:10-16:40
II-56 Ricardo Nalda-Molina
Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease.
Wednesday 15:10-16:40
II-57 Srividya Neelakantan
Population Pharmacokinetic/Pharmacodynamic Modeling of PF-06480605, an Anti-TL1A Antibody, in Healthy Subjects and Ulcerative Colitis Patients
Wednesday 15:10-16:40
II-58 Ida Neldemo
The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times
Wednesday 15:10-16:40
II-59 Bernard Ngara
A Semi-mechanistic population pharmacokinetic model quantifying hair concentrations of ritonavir-boosted atazanavir. A study of HIV infected Zimbabweans adolescents.
Wednesday 15:10-16:40
II-60 Laurent Nguyen
Pharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies
Wednesday 15:10-16:40
II-61 Laura Zwep
Hierarchical group LASSO with random effects: identification of high-dimensional omics-drug interactions predictive of treatment response in patient-derived tumor growth data
Wednesday 15:10-16:40
II-62 Joakim Nyberg
Implicit and efficient handling of missing covariate information using full random effects modelling
Wednesday 15:10-16:40
II-63 Boram Ohk
Population pharmacokinetic analysis of tacrolimus: The role of integrative pharmacogenetics and pharmacometabolomics
Wednesday 15:10-16:40
II-64 Andrés Olivares-Morales
Bayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker
Wednesday 15:10-16:40
II-65 Sean Oosterholt
Model-based optimisation of N-acetylcysteine for the treatment of paracetamol overdose
Wednesday 15:10-16:40
II-66 Fernando Ortega
Developing a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth
Wednesday 15:10-16:40
II-67 Taniya Paiboonvong
Development of physiologically based pharmacokinetic model of sitafloxacin in plasma and epithelial lining fluid
Wednesday 15:10-16:40
II-68 Semra Palic
Neopterin dynamics in pediatric patients after miltefosine treatment of visceral leishmaniasis
Wednesday 15:10-16:40
II-69 Robert Palmér
A novel joint modelling approach to estimating treatment effects on COPD exacerbations in the presence of differential discontinuations
Wednesday 15:10-16:40
II-70 Hyeonsoo Park
A population pharmacokinetic model of Glimepiride(Amaryl®)
Wednesday 15:10-16:40
II-71 Christophe Passot
A kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset.
Wednesday 15:10-16:40
II-72 Nathalie Perdaems
Translational PK-RO modelling for a mAb to predict the outcome of the first in human study
Wednesday 15:10-16:40
II-73 Carlos Perez-Ruixo
Exposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Wednesday 15:10-16:40
II-74 Soumya Perinparajah
Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV
Wednesday 15:10-16:40
II-75 Thomas Peyret
Development of a Quantitative Systems Pharmacology Model to Support Dosing of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, in Adult Patients with Hypoparathyroidism
Wednesday 15:10-16:40
II-76 Chiara Piana
Development of a translational pharmacokinetic-biomarker-efficacy model in mouse to support dose recommendation in human
Wednesday 15:10-16:40
II-77 Philippe Pierrillas
PK-PD modelling of C4 concentrations after administration of a FXR agonist in healthy volunteers and Hepatitis B patients
Wednesday 15:10-16:40
II-78 Nikhil Pillai
Single objective genetic algorithm based approach for optimal population pharmacokinetic/pharmacodynamics (PK/PD) model selection for tumor growth response
Wednesday 15:10-16:40
II-79 Vikram Prabhakar
QSP Model of Rheumatoid Arthritis, capturing range of clinical responses to Methotrexate and anti-TNF-a therapies
Wednesday 15:10-16:40
II-80 Sudeep Pradhan
Evaluation of study designs to test the intact nephron hypothesis
Wednesday 15:10-16:40
II-81 Mélanie Prague
In Silico Clinical Trials for Evaluation of HIV Short-Cycle strategies
Wednesday 15:10-16:40
II-82 Luna Prieto Garcia
Physiologically-based pharmacokinetic model for itraconazole and its metabolites: the importance of parameter sensitivity analysis
Wednesday 15:10-16:40
II-83 Alicja Puszkiel
Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism
Wednesday 15:10-16:40
II-84 Rajith Rajoli
PBPK Modelling of Atovaquone Long-acting Injectable Formulations
Wednesday 15:10-16:40
II-85 Chetan Rathi
Model-Informed selection of doses and sample size for a Phase 2a POC study of GSK3640254, a next generation HIV-1 maturation inhibitor
Wednesday 15:10-16:40
II-86 Michael Reed
Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform
Wednesday 15:10-16:40
II-87 Javier Reig-López
Validation of a Semi-mechanistic model with first-pass metabolism, two metabolic pathways and intestinal efflux transporter implemented in PhysPK biosimulation software.
Wednesday 15:10-16:40
II-88 Isabel Reinecke
Levonorgestrel-Containing Contraceptives: Comparison of Daily Doses and Exposure for Various Routes of Administration by an Integrated Population Pharmacokinetic Analysis
Wednesday 15:10-16:40
II-89 Dinko Rekic
Higher Febuxostat Exposure observed in Japanese Compared to Caucasian Subjects Independent of Bodyweight
Wednesday 15:10-16:40